Grants FY13-14

NMRC

• “Eye Surgery and Innovative Technologies (EyeSITe) Programme”.
  Prof Donald Tan; S$25,000,000.00

• “Multi-PlAtform STrategy for Eye Research 2 (MASTER-2)”.
  Prof Aung Tin; S$18,000,000.00

• “Multivalent Tetrabranched Peptides for Topical Fungal Infections: From Design to Delivery”.
  Dr Rajamani Lakshminarayanan; S$997,839.60

• “Characterization of PLEKHA7 role in Primary Angle Closure Glaucoma Pathogenesis”.
  A/Prof Eranga Nishanthie Vithana; S$1,458,951.00

• “SINGAPORE DIABETIC RETINOPATHY EPIDEMIOLOGY, BIOMARKERS AND IMAGING (DREAM) PROGRAM”.
  Prof Wong Tien Yin; S$5,000,000.00

• “The Singapore Indian Eye Study 2 (SINDI-2) – Prospective cohort study of 6-year incidence, risk factors, and impact of retinal and other major eye diseases”.
  Prof Wong Tien Yin; S$1,499,975.50

• “Investigation of LGR5 as a bona fide retinal stem cell marker”.
  Dr Shweta Singhal; S$200,000.00

• “Gestational Diabetes Mellitus And Risk Of Postpartum Metabolic Syndrome”.
  Dr Queenie Li Lingjun; S$199,988.00

• “Systemic T-cell Immunity defects in Immunocompetent Individuals with Cytomegalovirus Infection: New Modalities for the Detection and Surveillance for Viral Reactivation”.
  Dr Jay Sian Jyn Kuen; S$200,000.00

BMRC

• “Identification of Genetic biomarkers for disease progression in Angle Closure”.
  A/Prof Eranga Vithana; S$622,600.00

A*Star/ Duke-NUS/ MOH/ Others

• “Economic Impact and Health Burden of Eye Diseases in Singapore”.
  Dr Luo Nan; S$200,000.00

• “Profiling gene expression in age-related cataract using samples collected at the NUHS-TR Ocular Tissue Bank”.
  Dr Su Xinyi; USD$49,970.00

• “Efficacy of ATX inhibitors (RO6897779 and tool compound S32826) in rabbit and rodent models in lowering IOP: Proof of concept for ATX inhibition for treatment of primary open angle glaucoma”
  Dr Amutha Barathi Veluchamy; S$165,913.20

• “Using the laser induced CNV model in rats as Screening Platform to address angiogenic and inflammatory components of retinal eye disease”.
  Dr Amutha Barathi Veluchamy; S$156,232.11
  

• “The Singapore Integrated Diabetic Retinopathy Programme (SIDRP)”.
  Prof Wong Tien Yin; S$1,543,353

• “Hospital Performance Benchmarking: Evaluation of its Applicability in Eye Hospitals in Eight Asian Countries”.
  Dr Dirk De Korne; S$37,964.33

• “Prisms on Stroke Patients Encourages Rehabilitation Study (PROSPER study): A randomized controlled study on the effect of saccadic training and prisms on the functional ability with activities of daily living of stroke patients-a pilot study”.
  Dr Anna Tan; S$37,964.33

SingHealth

• “Novel Biomarkers for Diabetic Retinopathy”.
  Dr Gavin Tan; S$149,964.80

• “The Impact of Sleep Apnea on Diabetic Retinopathy (SADR) study”.
  Dr Merwyn Chew; S$50,000.00

• “Identification of environmental risk factors for POAG --- Questionnaire based study”.
  Dr Monisha Esther Nongpiur; S$50,000.00

• “Evaluating antibiotics frequency and concentration in killing moderately resistant strain of Pseudomonas aeruginosa”.
  Dr Li Jianguo; S$50,000.00

• “Design and Development of High Affinity Lipopolysaccharide (LPS) Binding Multivalent Peptides as Sensitizing Agents for Drug-resistant Gram-negative Pathogens”.
  Dr Rajamani Lakshminarayanan; S$149,300.00

Commercial

• “A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients (C-12-008)”.
  Adj. A/Prof Ho Ching Lin; S$38,577.22

• “Corneal femtosecond laser animal studies”.
  A/Prof Jodhbir Mehta; S$107,000.00

• “An Open Label (Stage 1) and Randomized (Stage 2), 24-Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients with Open-Angle Glaucoma or Ocular Hypertension (192024-041D)”.
  Prof Aung Tin; S$ 412,398.08

• “The Reliability and Sensitivity of Two-Field Fundus Photography in the Screening  and Classification of Diabetic Retinopathy (DR) using the new Confocal Scanning Laser Ophthalmoscopy (cSLO)”.
  Dr Carol Cheung; S$ 26,078.55

• “A 24-month, phase IV, randomized, double masked, multicenter study of ranibizumab monotherapy or ranibizumab in combination with verteporfin photodynamic therapy on visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy”.
  A/Prof Gemmy Cheung; S$ 365,994.97

• “Prospective, single-centered, switching study of 0.0015% tafluprost ophthalmic solution in primary open-angle glaucoma and ocular hypertension patients with corneal disorders (12-003)”.
  Adj. A/Prof Ho Ching Lin; S$126,091.49

• “A 12-month, Randomized,  Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5 mg Ranibizumab Intravitreal Injections in Patients with Visual Impairment due to Vasculr endothelial growth factor (VEGF) driven macular edema (ME), CRFB002G2302”.
  Dr Ranjana Mathur; S$117,578.97

• “The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucome Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomised, Controlled Clinical Trial (Hydrus 4 study)”.
  Adj. A/Prof Shamira Perera; S$178,716.11